(Reuters) – British drugmaker AstraZeneca Plc told Reuters on Tuesday that its COVID-19 vaccine should be effective against the new coronavirus variant, adding that studies were under way to fully probe the impact of the mutation.
“AZD1222 (AstraZeneca’s vaccine candidate) contains the genetic material of the SARS-CoV-2 virus spike protein, and the changes to the genetic code seen in this new viral strain do not appear to change the structure of the spike protein,” an AstraZeneca spokesperson said in an email.
(Reporting by Kanishka Singh in Bengaluru; Editing by Leslie Adler)
